Trial Profile

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narmafotinib (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ACCENT
Sponsors Amplia Therapeutics Limited

Most Recent Events

19 Feb 2025 According to Amplia Therapeutics Limited Media Release, data from this ongoing ACCENT trial in pancreatic cancer, was presented overnight at the prestigious Keystone meeting Tumor Microenvironment: Metastasis and the Host in Banff, Canada.
05 Feb 2025 Planned End Date changed from 1 May 2025 to 1 May 2026.
05 Feb 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com